1) González-López E, Gellego-Delgado M, Guzzo-Merello G, et al:Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 36:2585-2594, 2015
2) Falk RH, Alexander KM, Liao R, et al:AL(Light-Chain)Cardiac Amyloidosis:A Review of Diagnosis and Therapy. J Am Coll Cardiol 68:1323-1341, 2016
3) Ruberg FL, Grogan M, Hanna M, et al:Transthyretin Amyloid Cardiomyopathy:JACC State-of-the-Art Review. J Am Coll Cardiol 73:2872-2891, 2019
4) Grogan M, Scott CG, Kyle RA, et al:Natural History of Wild-Type Transthyretin Cardiac Amyloidosis and Risk Stratification Using a Novel Staging System. J Am Coll Cardiol 68:1014-1020, 2016
5) Maurer MS, Schwartz JH, Gundapaneni B, et al:Tafamidis Treatment for Patients with Transthyretin Amyloid Cardiomyopathy. N Engl J Med 379:1007-1016, 2018
6) Palladini G, Dispenzieri A, Gertz MA, et al:New criteria for response to treatment in immunoglobulin light chain amyloidosis based on free light chain measurement and cardiac biomarkers:impact on survival outcomes. J Clin Oncol 30:4541-4549, 2012
7) Ericzon BG, Wilczek HE, Larsson M, et al:Liver Transplantation for Hereditary Transthyretin Amyloidosis:After 20 Years Still the Best Therapeutic Alternative? Transplantation 99:1847-1854, 2015
8) Phelan D, Thavendiranathan P, Popovic Z, et al:Application of a parametric display of two-dimensional speckle-tracking longitudinal strain to improve the etiologic diagnosis of mild to moderate left ventricular hypertrophy. J Am Soc Echocardiogr 27:888-895, 2014
9) Castano A, Haq M, Narotsky DL, et al:Multicenter Study of Planar Technetium 99m Pyrophosphate Cardiac Imaging:Predicting Survival for Patients With ATTR Cardiac Amyloidosis. JAMA Cardiol 1:880-889, 2016
10) Quarta CC, Gonzalez-Lopez E, Gilbertson JA, et al:Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis. Eur Heart J 38:1905-1908, 2017